第一章 总 则 第一条 为规范鲁商福瑞达医药股份有限公司（以下简称"上市公司"或"公 司"）募集资金的使用与管理，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司证券发行注册管理办法》《上市公司募集资金监管规则》 《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》，制定本规定。 第二条 本规定所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计划 募集的资金。 本规定所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 募集资金应严格限定用于公司在发行申请文件中承诺的募集资金投 资项目（以下简称"募投项目"）。公司变更募投项目必须在董事会审议后提交 股东会批准，并履行信息披露义务和其他相关法律义务。 第四条 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防范 投资风险，提高募集资金使用效益。 公司的董事和高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控公司擅自或者变相改变募集资金用途。 第二章 募集资金存储 （五）保荐人或者独立财务顾问可以随时到商业 ...

证券代码：301137 证券简称：哈焊华通 公告编号：2025-057 哈焊所华通（常州）焊业股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 哈焊所华通（常州）焊业股份有限公司（以下简称"公司"或"哈焊华通"） 第五届董事会第二次会议通知于 2025 年 8 月 8 日以书面及电子邮件的方式发出， 会议于 2025 年 8 月 20 日以现场结合通讯表决方式在公司六楼会议室召开，本次 会议应出席董事 9 人，实际出席董事 9 人（其中：雷振以通讯表决方式出席会议； 周金静授权委托陈春鑫出席会议并行使表决权）。公司高级管理人员列席了本次 会议。本次会议由公司董事长雷振先生召集并主持。会议的召集、召开及表决程 序符合《中华人民共和国公司法》及《公司章程》的规定，会议决议合法有效。 二、董事会会议审议情况 经全体董事审议，本次会议以记名投票的方式表决通过了相关议案并形成 如下决议： （一）审议通过《关于<2025 年半年度报告全文及摘要>的议案》； 经审议，董事会认为：公司《2025 年半年度报告 ...

证券代码：301120 证券简称：新特电气 公告编号：2025-052 新华都特种电气股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据《深圳证券交易所创业板股票上市规则》《上市公司募集资金监管规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法 律、法规、规范性文件的规定，新华都特种电气股份有限公司（以下简称"公司"或"新 特电气"）就 2025 年半年度募集资金存放与使用情况作如下专项报告： 一、公司首次公开发行股票募集资金基本情况 （一）募集资金金额及到账情况 经中国证券监督管理委员会《关于同意新华都特种电气股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕378 号）同意注册，公司首次公开发行人民 币普通股（A 股）股票 6,192.00 万股，每股面值 1 元，每股发行价格为 13.73 元，募 集资金总额为 85,016.16 万元。扣除各项发行费用后，实际募集资金净额为 75,468.97 万元。中审众环会计师事务所（特殊普通合伙）已对公司首次公开发行股票的资金到 位情况进行了审 ...

Core Points - The report details the fundraising and usage status of Luopute Technology Group Co., Ltd. as of June 30, 2025, confirming compliance with regulatory requirements [1][2][3] - The total amount raised through the initial public offering (IPO) was RMB 904,287,300, with a net amount of RMB 818,787,012 after deducting issuance costs [1][3] - As of June 30, 2025, the company has utilized RMB 611,950,092 for investment projects and has no remaining balance in the fundraising account [1][3] Fundraising Overview - The actual fundraising amount was RMB 904,287,300, which was fully received by February 10, 2021 [1] - The net amount after deducting issuance costs was RMB 818,787,012 [1] - The company has received a total of RMB 19,384,843.91 in interest income from the fundraising [1] Fund Usage - As of June 30, 2025, the company has used RMB 611,950,092 for investment projects and RMB 85,999,500 for permanent working capital [1][3] - The company has also used RMB 50,000,000 for temporary working capital and RMB 2,558,967.20 for share repurchase [1][3] - The remaining balance in the fundraising account was RMB 51,298,106.93 [3] Fund Management - The company has established a fundraising management system in compliance with relevant regulations, ensuring proper storage and usage of funds [1] - Multiple banks have signed tripartite supervision agreements for the management of fundraising accounts [1] - The company has approved the use of part of the idle fundraising for temporary working capital, not exceeding RMB 10,000,000 [1][5] Project Updates - The "Research and Development Center Construction Project" has been completed, and the remaining funds have been permanently supplemented into working capital [1][5] - The "Market Expansion and Operation Service Network Construction Project" has had its expected usable status date extended to December 2025 due to external market conditions [5]

Core Viewpoint - The company, Guilin Rhine Biotechnology Co., Ltd., is reducing the investment scale of certain fundraising projects and will permanently supplement its working capital with the remaining funds from these projects [2][10]. Fundraising Overview - The company raised a net amount of approximately 961.11 million RMB from a non-public stock issuance, which was approved by the China Securities Regulatory Commission [2]. - The funds were deposited in a dedicated account, and the management of these funds adheres to relevant regulations to ensure proper usage [3]. Fund Management and Usage - As of July 31, 2025, the total balance in the fundraising account was 1.63 million RMB, with a total interest income of approximately 1.48 million RMB [3]. - The company has directly invested approximately 652.66 million RMB into various projects, including 573.96 million RMB for the Stevia Extraction Factory and 78.70 million RMB for the Rhine Natural Health Products Research Institute [3][4]. Project Completion and Fund Reduction - The Stevia Extraction Factory project has met the completion criteria, with a total investment of 573.96 million RMB, leaving a surplus of approximately 36.32 million RMB [7][9]. - The Rhine Natural Health Products Research Institute project has been partially completed, with 78.70 million RMB invested and an estimated remaining payment of 37.08 million RMB [8][9]. Impact of Fund Reduction - The decision to reduce the investment scale and reallocate surplus funds is aimed at enhancing the company's liquidity and financial structure, thereby supporting sustainable development and maximizing shareholder value [10][9]. - The company’s current research and development capabilities are deemed sufficient to support ongoing business operations and future product innovations [9]. Approval Process - The board of directors and the supervisory board have approved the proposal to reduce the investment scale and reallocate surplus funds, which will be submitted for shareholder approval [10][11].

证券代码：002557 证券简称：洽洽食品 公告编号：2025-060 债券代码：128135 债券简称：洽洽转债 洽洽食品股份有限公司 第六届监事会第十五次会议决议的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 洽洽食品股份有限公司（以下简称"公司"）第六届监事会第十五次会议通 知于2025年8月16日以书面及邮件方式通知全体监事，并于2025年8月21日在公司 四楼会议室召开，本次会议采用现场方式召开。会议由监事会主席宋玉环女士主 持，全体监事出席了会议。本次会议应到监事3名，实到监事3名，符合《中华人 民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经全体监事审议表决，形成如下决议： （一）会议以 3 票同意，0 票反对，0 票弃权，通过了《关于<2025 年半年 度报告>及摘要的议案》； 公司《2025 年半年度报告》详见巨潮资讯网（www.cninfo.com.cn），公司 《2025 年半年度报告摘要》刊登在《中国证券报》《证券时报》《上海证券报》 《证券日报》和巨潮资讯网（www.cninfo. ...

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the actual usage of funds by Xinjiang Tianrun Dairy Co., Ltd., emphasizing compliance with regulations and the management of raised funds. Group 1: Fundraising Overview - The company raised a total of RMB 990 million through the issuance of convertible bonds, with a net amount of RMB 979.31 million after deducting issuance costs [1][2] - As of June 30, 2025, the cumulative amount used from the raised funds was RMB 647.87 million, leaving a balance of RMB 334.41 million [1][2] Group 2: Fund Management - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, which was approved by the shareholders' meeting [1][2] - Funds are stored in dedicated accounts, and no non-fund-related deposits have been made [1][2] Group 3: Fund Usage - The company has used RMB 14.05 million from the raised funds in the first half of 2025, with a total of RMB 633.82 million used in previous years [1][2] - The company has replaced self-raised funds with RMB 350.36 million from the raised funds for project investments and issuance costs [2][3] Group 4: Cash Management - The company has approved the use of temporarily idle funds for cash management, with a maximum daily balance of RMB 400 million, and has invested RMB 334.41 million in various financial products [2][3] - The total income from cash management activities during the reporting period was RMB 2.52 million [2][3] Group 5: Project Status - The completion date for the "Annual Production of 200,000 Tons of Dairy Products Processing Project" has been postponed from December 31, 2024, to December 31, 2025, due to construction delays [2][3] - The company has not encountered any significant changes in the feasibility of the projects funded by the raised capital [2][3]

北矿科技股份有限公司 募集资金管理办法 (2025 年 8 月) 第一章 总则 第一条 为规范北矿科技股份有限公司（以下简称"公司"）募集资金的使用 与管理，提高募集资金使用效益，保护投资者的合法权益，依据《中华人民共和 国公司法》《中华人民共和国证券法》《首次公开发行股票注册管理办法》《上 市公司证券发行注册管理办法》《上市公司信息披露管理办法》《上市公司募集 资金监管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自 律监管指引第 1 号——规范运作》及《北矿科技股份有限公司章程》（以下简称 "《公司章程》"）等规定，结合公司实际情况，制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划 募集的资金。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业政 策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主营 业务，有利于增强公司竞争能力和创新能力。 《监管规则适用指引——上市类第 1 号》对上市 ...

洽洽食品股份有限公司 募集资金管理制度 为规范洽洽食品股份有限公司（以下简称"公司"）募集资金管理，提高募 集资金使用效率，根据《中华人民共和国公司法》《中华人民共和国证券法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》《上市公司募集资金监管规则》等法律、法规、规范 性文件以及《洽洽食品股份有限公司章程》（以下简称"《公司章程》"）的规 定，结合本公司实际情况，特制定本制度。 第一章 总 则 第一条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计 划募集的资金监管。本制度所称超募资金是指实际募集资金净额超过计划募集资 金金额的部分。 第二条 公司对募集资金的使用必须符合有关法律、行政法规和规范性文件 的规定。募集资金应按照招股说明书或募集说明书所列用途使用，未经股东会批 准不得改变承诺的资金用途。 第四条 公司董事会应当对募集资金投资项目的可行性进行认真分析，确信 投资项目具有较好的市场前景和盈利能力，有效防范投资风险，提高募集资金使 用效益。 募集资金的使用应坚持周 ...

Group 1 - The company held its 16th meeting of the second board of directors, where all 13 attending directors voted in favor of the proposals presented [1][2] - The board approved the profit distribution plan for the first half of 2025, which will be submitted for shareholder meeting review [2] - The board also approved the 2025 half-year report and its summary, which had been reviewed by the audit committee prior to the board meeting [2][3] Group 2 - A special report on the management and use of raised funds for the first half of 2025 was also approved unanimously by the board [3] - The board agreed to convene the second extraordinary general meeting of shareholders in 2025, with all directors voting in favor [3]